Pharmaceutical Executive
Marketers fear a Catch-22 if they have to write research summaries that FDA considers illegal promotion.
Pharmaceutical Executive-05-21-2009
- News
- Academy
- Multimedia
- Conferences
- Publications
- Partner Perspectives
- Resources
- Subscribe